对NF-1-相关瘤的过去,现在和未来的治疗策略
Brian Na1, Shilp R Shah2, Harish N Vasudevan3,4
1Department of Neurology, UCLA Neuro-Oncology Program, University of California Los Angeles, Los Angeles, CA, 90095, USA.
Current oncology reports
|May 6, 2024
概括
神经纤维素瘤类型1 (NF-1) 治疗侧重于Ras通路的抑制. 虽然MEK抑制剂在某些瘤中表现出成功,但对于侵袭性癌症和不响应癌症需要新的策略.
科学领域:
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
- 分子生物学分子生物学
背景情况:
- 神经纤维素瘤类型1 (NF-1) 是一种遗传性疾病,其特征是由于NF1基因突变导致的瘤倾向.
- NF1基因编码神经纤维素,一种负面调节Ras信号通路的蛋白质,对细胞生长和分化至关重要.
研究的目的:
- 对NF-1相关瘤的过去,现在和未来的治疗策略进行审查.
- 讨论针对Ras路径和超越的治疗方法的演变.
主要方法:
- 对NF-1相关瘤的治疗策略的文献综述.
- 将治疗方法分为历史,当前和未来的方法.
主要成果:
- 通过向Ras信号,MEK抑制已在形神经纤维瘤和低级质瘤中取得临床成功.
- 针对Ras信号的单疗法存在局限性,特别是在恶性外围神经膜瘤和高度质瘤等攻击性癌症中.
结论:
- 目前的研究重点是并行途径抑制和组合疗法.
- 未来的方向包括免疫疗法,先进的药理学和基因传递,以更有效地治疗NF-1瘤.
更多相关视频
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
1.1K
07:10Orthotopic Xenografting of Human Luciferase-Tagged Malignant Peripheral Nerve Sheath Tumor Cells for in vivo Testing of Candidate Therapeutic Agents
Published on: March 7, 2011
18.6K
相关概念视频
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
01:27Tumor Immunotherapy
518
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
518
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
159
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
159